The introduction of ICIs targeting the PD-1/PD-L1 pathway in recent years has resulted in further breakthroughs in the fate of patients with metastatic HNSCC, although the results remain unsatisfactory when compared to other tumors such as melanoma and lung cancer (51). This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.